Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study

Similar Items

• Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study
  od: Meyers, Kristin J., i dr.
  Izdano: (2017)
• Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study
  od: McDonnell, David P., i dr.
  Izdano: (2014)
• Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment
  od: Detke, Holland C., i dr.
  Izdano: (2014)
• Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
  od: Ascher-Svanum, Haya, i dr.
  Izdano: (2014)
• A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
  od: Atkins, Susan, i dr.
  Izdano: (2014)